Small experimental studies in humans have shown that supplementation of growth hormone (the up‐stream physiological regulator of IGF‐I) leads to losses in fat and gains in lean mass 8, and Laron syndrome (genetic insensitivity to growth hormone) is characterized by high fat mass levels which are reversed by IGF‐I therapy 9. Here, IGF1 is linked to Laron syndrome.